A 38-year-old male with treatment-resistant schizophrenia has failed adequate trials of risperidone and aripiprazole. The PMHNP plans to initiate clozapine. The FDA substantially modified the formal Clozapine REMS program in late 2024 / early 2025, but ANC monitoring remains the standard of care. Which of the following best describes the recommended monitoring before and during clozapine treatment?